Trials / Approved For Marketing
Approved For MarketingNCT00338247
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lapatinib + capecitabine | Experimental |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2006-06-20
- Last updated
- 2016-04-06
Locations
453 sites across 45 countries: United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Cyprus, Czechia, Denmark, Estonia, Finland, Germany, Greece, Hong Kong, Iceland, Indonesia, Ireland, Israel, Italy, Luxembourg, Malaysia, Malta, Mexico, Netherlands, New Zealand, Peru, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom
Source: ClinicalTrials.gov record NCT00338247. Inclusion in this directory is not an endorsement.